Brinton Pharma receives DCGI nod to market favipiravir in IndiaJuly 24, 2020 0 By FM
Brinton Pharmaceuticals has recently announced that the company received approval from the Drugs Controller General of India (DCGI) to market the antiviral drug favipiravir under the brand name Faviton to treat mild to moderate COVID 19 patients.
The favipiravir tablets will be available in 200mg dose in a strip of 10 tablets and 50 tablets with a shelf-life of 90 days, said the company.
Several emerging global clinical evidence has suggested favipiravir as an effective treatment option in the management of mild to moderate COVID 19 cases. The drug has shown unique activity against RNA viruses. Upon intake, the drug is converted to the ribofuranosyl triphosphate derivative by host enzymes which selectively inhibit the influenza viral RNA-dependent RNA polymerase enzyme necessary for their replication.